Susan G Komen  
I've Been Diagnosed With Breast Cancer Someone I Know Was Diagnosed Share Your Story Join Us And Stay Informed Donate To End Breast Cancer
Home > Understanding Breast Cancer > Breast Cancer Research > Table 49: Combined modality treatment and overall survival in inflammatory breast cancer

  


Table 49: Combined modality treatment and overall survival in inflammatory breast cancer

This summary table contains detailed information about research studies. Summary tables offer an informative look at the science behind many breast cancer guidelines and recommendations. However, they should be viewed with some caution. In order to read and interpret research tables successfully, it is important to understand some key concepts. Learn how to read a research table.

Introduction: Inflammatory breast cancer is a rare, but aggressive form of breast cancer. It is treated with a combination of surgery, radiation therapy and chemotherapy, and may include hormone therapy and/or targeted therapy. This is often called combined modality treatment because multiple therapies are used.  

With combined modality treatment, five-year overall survival rates for inflammatory breast cancer range from about 30 to 70 percent (see studies below). With modern treatments available today, survival for women with inflammatory breast cancer appears to be improving. One study found three-year overall survival was 63 percent for women diagnosed before 2006 and 82 percent for women diagnosed after 2006 [1].

Study selection criteria: Clinical trials with 50 or more participants on combined modality treatment with at least five years follow-up.

Study 

Study Population (number of participants) 

Treatments Studied 

5-year Overall Survival Rate 

Clinical trials 

Palangie et al. [2]

223

Chemotherapy>>radiation therapy>>chemotherapy with or without immunotherapy with or without hormone therapy with or without mastectomy

41%

Ueno et al. [3]

178

Chemotherapy>>radiation therapy>>chemotherapy

OR

Chemotherapy>>mastectomy>>chemotherapy>>radiation therapy

40%

Chevallier et al. [4]

178

Chemotherapy>>radiation therapy with or without mastectomy with or without chemotherapy

32%

Attia-Sobol et al. [5]

103

Chemotherapy>>radiation therapy>>chemotherapy

OR

Chemotherapy with or without radiation therapy with or without surgery with or without radiation therapy>>chemotherapy

55%

Untch et al. [6]

91

Dose-dense or standard chemotherapy>>lumpectomy>>chemotherapy>>radiation therapy

OR

Dose-dense or standard chemotherapy>>mastectomy with or without radiation therapy>>chemotherapy

65%*

Perez et al. [7]

86

Radiation therapy>>mastectomy>>chemotherapy

38%* 

Harris et al. [8]

54

Chemotherapy>>radiation therapy with or without mastectomy>>chemotherapy

OR

Chemotherapy>>mastectomy>>radiation therapy>>chemotherapy

OR

Mastectomy>>chemotherapy>>radiation therapy>>chemotherapy

56%

* Estimate from figure in article

† Breast cancer survival rather than overall survival


 References 

  1. Tsai CJ, Li J, Gonzalez-Angulo AM, et al. Outcomes after multidisciplinary treatment of inflammatory breast cancer in the era of neoadjuvant HER2-directed therapy. Am J Clin Oncol. 2013 May 2 [Epub ahead of print].
  2. Palangie T, Mosseri V, Mihura J, et al. Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer. 7:921-7, 1994.
  3. Ueno NT, Buzdar AU, Singletary SE, et al. Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. Cancer Chemother Pharmacol. 40:321-9, 1997.
  4. Chevallier B, Bastit P, Graic Y, et al. The Centre H. Becquerel studies in inflammatory non-metastatic breast cancer. Combined modality approach in 178 patients. Br J Cancer. 67:594-601, 1993.
  5. Attia-Sobol JA, Ferriere J, Cure H, et al. Treatment results, survival and prognostic factors in 109 inflammatory breast cancers: univariate and multivariate analysis. Eur J Cancer. 29A:1081-1088, 1993.
  6. Untch M, Möbus V, Kuhn W, et al. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J Clin Oncol. 27(18):2938-45, 2009.
  7. Perez CA, Fields JN, Fracasso PM, et al. Management of locally advanced carcinoma of the breast. II. Inflammatory Carcinoma. Cancer. 74:466-76, 1994.
  8. Harris EER, Schultz D, Bertsch H, et al. Ten-year outcome after combined modality therapy for inflammatory breast cancer. Int J. Radiation Oncology Biol Phys. 55:1200-1208, 2003.

Updated 01/13/14